Collection of Human Metabolic Tissues

Obesity Clinical Trial

— COMET  

Official title:

Study of New Determinants of Type 2 Diabetes in Severe Obesity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02861781
• Other study ID #: RECHMPL15_0271
• Secondary ID: 2015-A01193-46UF
• Status: Recruiting
• Start date: February 2, 2016
• Est. completion date: September 2024

Study information

• Verified date: May 2024
• Source: University Hospital, Montpellier
• Contact: Florence Galtier, MD
• Email: f-galtier[@]chu-montpellier.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This project aims at identifying new determinants of type 2 diabetes in severe obesity. To do so, a biological collection, including tissues of interest in the field of metabolism, will be collected during bariatric surgery in obese patients. Three different groups of metabolic status of patients, corresponding to different stages of evolution of the disease, will be constituted: type 2 diabetes, insulin resistance, insulin sensitivity.

The main objective is to compare, between these 3 groups of patients, several biological processes that may be involved in the pathophysiology of type 2 diabetes and disorders associated with obesity, including:

• Abnormalities of the transcriptome, proteome, metabolome in all target tissues (plasma, serum, muscle, subcutaneous and visceral adipose tissue, omental artery, liver)

• Identification of metabolic signatures, protein and miRNA in plasma

• Immunoinflammatory response in adipose tissue

• Polymorphisms SNP from whole blood

• Histological analysis of tissue sections This main objective will be studied on samples taken at the time of surgery Secondary objectives will be to study the changes in metabolites, proteins and miRNA in plasma level 3 and 12 months after the completion of surgery, according to the initial metabolic state.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 270
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Written informed consent

2. Age 18 - 65 years inclusive at surgery

3. IMC > 35

4. Subject qualified for bariatric surgery (sleeve gastrectomy or gastric bypass)

5. Specific criteria :

• Type 2 diabetes group (D) (90 patients) : type 2 diabetes according to ADA criteria

• Insulin resistance non diabetes group (IR) (80 patients) : HOMA-IR criteria = 3

• Insulin Sensitivity non diabetes group (N) (100 patients) : N1.HOMA-IR criteria < 3

Non inclusion Criteria:

1. Vulnerability according to article L1121-6 of the Public Health Code

2. Protected adult or unability to give consent according to article L1121-8 of the Public Health Code

3. Unability to understand the design and aims of the study or to communicate with the investigator

4. Non affiliation to a social security system

5. Prior bariatric surgery (except lap-band procedure)

6. Serologic profile indicating hepatitis B, hepatitis C or HIV infection

7. Inflammatory, infectious or autoimmune disease (current or in the previous 3 month)

8. Malignancies within 5 years prior to inclusion or not considered as treated curatively

9. Concomitant use of steroids or NSAI or use in the 8 days before surgery

10. alcohol abuse/addiction

11. Anticipated poor compliance to study procedures

12. Other type of diabetes than type 2

Exclusion Criteria :

1. Cancelled bariatric surgery

2. Tissue collection not possible during the bariatric surgery

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Insulin Resistance
• Obesity

Intervention

Other:
• Collection of blood samples and tissues
Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits

Locations

Country	Name	City	State
France	Hôpital Saint Eloi	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	comparison of metabolites		At baseline (day of surgery)
Primary	comparison of proteins levels	in liver, muscle, adipose tissue and plasma according to metabolic state	At baseline (day of surgery)
Primary	comparison of miRNA	in liver, muscle, adipose tissue and plasma according to metabolic state	At baseline (day of surgery)
Secondary	changes in metabolites in plasma level		3 and 12 months after the completion of surgery
Secondary	changes in proteins in plasma level		3 and 12 months after the completion of surgery
Secondary	changes in miRNA in plasma level		3 and 12 months after the completion of surgery